HCM
ONCT

Hollencrest Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Hollencrest Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-550
Closed -$8.64K – 1189
2023
Q1 		$8.64K Hold
550
– – ﹤0.01% 770
2022
Q4 		$11K Buy
+550
New +$10.9K ﹤0.01% 715

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $4.53B AUM 21.1% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Hollencrest Capital Management's ONCT Position: Q2 2023 in Review

Hollencrest Capital Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2023, closing a stake of 550 shares — an estimated $8.64K sold.

Hollencrest Capital Management first reported a position in ONCT in Q4 2022 and held it in 2 quarters. The position peaked at $11K in Q4 2022. 52 funds tracked by Wall St. Rank hold ONCT as of Q2 2023.

  • Hollencrest Capital Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Hollencrest Capital Management sold 550 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $8.64K.
  • Hollencrest Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Hollencrest Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $11K in Q4 2022.
  • 52 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Hollencrest Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.